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Poster Session I 51deplete plasma, but not the RBC. A retrospective analysis was per-
formed on 240 pediatric patients transplanted with PD (128) or
RCR (112) CB. PD CB came from StemCyte and were transplanted
at many US & international centers - 60 ALL, 35 AML, 6 MDS, 5
lymphoma, 4 JMML, and 18 other malignancies. The other patients
received RCR CB products from various CB banks and were trans-
planted at the University of Arizona Medical Center - 56 ALL, 32
AML, 9 CML, 6 MDS, 4 lymphoma, and 5 other malignancies.
Of the 74% PD and 46% RCR cases with known disease status,
27% versus 24% were early, 45% versus 52% intermediate, and
27% and 18% advanced per IBMTR for PD and RCR respectively.
Median age for PD and RCR patients were 6 (range 0.5–15) and 7
years (range 0.5–15) respectively; median weight were 21 kg (range
5–92) for PD and 25 kg (range 7–104) for RCR, with 65%. and 55%
males respectively. Median # HLA ABDR matches were 5.0 for
both groups; however, median pre-freeze and post-thaw TNC
dose were 6.8  107/kg and 5.3  107/kg for PD patients (78% re-
covery) and 4.6  107/kg and 3.3  107/kg for RCR patients (72%
recovery); non-myeloablative conditioning accounted for 12% of
PD and 3% of RCR patients. Cumulative incidence estimates
were used for engraftment (unevaluable category not used), and Ka-
plan-Meier estimates were used for relapse, TRM, OS and RFS
rates. A matched-pair analysis was also performed by matching
a PD patient to each RCD patient based on age, weight, # HLA
matches, cell dose, disease, and disease status if available and are
summarized below. The results demonstrate that 1) Foregoing
RCR may result in higher cell dose products being selected for
transplantation; 2) unrelated PD CBT can be performed safely
with superior engraftment and TRM in diverse pediatric patients
with malignancies, and appear to trend towards improvement for
overall survival on univariate analysis; 3) matched pair analysis
even with cell dose matched may show a potential advantage of
PD CB for platelet engraftment and TRM.
Outcome Summary
Plt Plt 1-Yr 100-Day &ANC500 20 K 50 K Relapse* 1-Yr TRM 1-Yr OS 1-Yr RFS*PD Patients 89 ± 6% 69 ± 6% 65 ± 6% 29 ± 5% 15 ± 3%,
23 ± 4%60 ± 5% 51 ± 5%RCR Patients 85 ± 6% 55 ± 6% 51 ± 6% 17 ± 5%* 30 ± 4%,
45 ± 5%49 ± 5% 44 ± 5%*Cox RR &
P-value
(RCR
Reference)0.81 0.13 1.60 0.007 1.41 0.06 0.49 0.002 0.74 0.11
(for death)Matched Pair
AnalysisANC500 Plt 20 K Plt 50 K Relapse TRM OS RFSP-value NS 0.005 0.02 0.004 NS NSIn favor of PD PD PDNS 5 Not significant.
*Insufficient data on disease status of RCR patients precludes mean-
ingful analysis.134
CLINICAL CHARACTERISTICS OF EARLY ONSET NON-INFECTIOUS PUL-
MONARY COMPLICATIONS FOLLOWING CORD BLOOD TRANSPLANTA-
TION
Wake, A., Uchida, N., Ishiwata, K., Takagi, S., Tsuji, M., Kato, D.,
Yamamoto, H., Seo, S., Matsuno, N., Masuoka, K., Miyakoshi, S.,
Makino, S., Yoneyama, A., Taniguchi, S. Toranomon Hospital, Tokyo,
Japan.
Early onset non-infectious pulmonary complications (EONIPC),
such as idiopathic pneumonia syndrome (IPS) are fatal disorders
following allogeneic SCT. There has been little information on
NIPC following cord blood transplantation (CBT). We tried to
characterize NIPC after CBT.
We reviewed medical records of 246 patients (291 transplants)
with hematological diseases who had received CBT between Jan.2002 and Dec. 2006 at Toranomon Hospital, Tokyo, Japan. Median
age was 55 years (17–79). Most of them had diseases in advanced sta-
tus (n5 255). Most of the pre-transplant conditioning were reduced
intensity consisted of fludarabine, melphalan and TBI 4Gy (n 5
223). Most of GVHD prophylaxis were calcineurin inhibitor only;
cyclosporine (CSP) (n 5 102) or tacrolimus (Tac) alone (n 5
173). HLA disparities were as follows; 6/6 (n 5 14), 5/6 (n 5 73),
4/6 (n 5 198), and 3/6 (n 5 6). Diagnosis of NIPC was made by
Chest X-ray, computed tomography, bronchoscopy, and pulmo-
nary function test. Infectious complications were excluded by posi-
tive result of culture, galactomannan test, and RT-PCR of sputum,
pleural effusion and BAL fluid.
The incidence of NIPC was 33.7% (n 5 98). EONIPC (95 pa-
tients) were developed within 100 days after transplant (median,
17 days, range, 2–57), which can be subdivided into 2 on the basis
of presence (n 5 48) or absence (n 5 47) of pleural effusion (PE).
Late onset NIPC (LONIPC) were observed in only 11 cases
(4.5%), including 3 cases of COP, 6 of IP, and 2 of BO. Multivariate
analysis revealed 3 risk factors for EONIPC with PE; GVHD pro-
phylaxis with CSP over Tac (p 5 0.036, RR 1.65), grade III-IV
acute GVHD over grade 0-II (p 5 0.007, RR 1.84), and 2 and
greater HLA mismatch over less than 2 (p 5 0.046, RR 1.587).
The CT finding of NIPC with PE revealed ground-glass opacity
of lung field, similar to that of COP. NIPC with PE responded fa-
vorably to low dose corticosteroid therapy as same as COP. In con-
trast to low 1-year overall survival (OS) of NIPC without PE
(11.1%, 95%CI: 1.9–20.3), that of NIPC without PE was signifi-
cantly high (53.1%, CI: 38.8–67.4).
The incidence of EONIPCs was high, whereas that of LONIPCs
was low after reduced-intensity CBT using single calcineurin inhib-
itor as GVHD prophylaxis. Further accumulation and more precise
investigation of laboratory and clinical data are warranted to clarify
the biological mechanism of EONIPC with PE and without PE or
to descriminate IPS from engraftment syndrome or capillary leak
syndrome.135
A TWO STEP APPROACH TO HAPLOIDENTICAL ALLOGENEIC HEMATO-
POIETIC STEM CELL TRANSPLANTATION (HSCT) FOR HIGH RISK PA-
TIENTS WITH HEMATOLOGIC DISORDERS
Grosso, D., Brunner, J., Carabasi, M., Dessain, S., Filicko-O’Hara, J.,
Mookerjee, B., O’Hara, W., Tedesco, N., Wagner, J.L.,
Flomenberg, N. Thomas Jefferson University, Philadelphia, PA.
Post transplant cyclophosphamide (CTX) has been utilized to in-
duce donor host tolerance in allogeneic HSCT. While promising,
the long term risk of MDS and AML from exposure of the graft
to CTX is unknown, and the optimal T cell dose to deliver using
this approach remains undefined. To address these issues, 12
high-risk patients underwent haploidentical HSCT from related
donors for disorders of hematopoiesis using a two step approach.
Nine of 12 (75%) patients had evidence of disease at the time of
HSCT. In the GVH direction, 10 of 12 were 4/8 matches with their
donors at HLA-A, B, C and DRB1; the other 2 patients were 5/8
and 6/8 matches. Nine of the 12 patients were given a myeloablative
conditioning regimen of TBI (1.5 Gy) BID on days -9 through -6.
Three received a nonmyeloablative conditioning regimen of fludar-
abine and ARA-C on days-11 through -8 and one 2 Gy fraction of
TBI on day -6. The patients received 2  108/kg of their donor’s
CD31 lymphocytes after completion of TBI on day -6, followed
by rest days on day -5 and -4. On days -3 and -2, CTX was given
at a dose of 60 mg/kg/day for the purpose of tolerization of the do-
nor lymphocytes. On day 0, donor CD341 cells were infused. When
possible, the number of non-tolerized T-cells in the CD341 prod-
uct was limited to 5  104/kg. Tacrolimus and CellCept were used
as GVHD prophylaxis. All of the patients developed fevers between
DLI and CTX. Some patients also developed mild diarrhea and
a rash, which in one case was biopsy-positive for GVHD. All pa-
tients engrafted. GVHD was generally mild, and easily controlled
with corticosteroids which could be rapidly tapered in all but one
patient. Five patients have died, three of relapsed disease and two
of infections. An additional patient is alive, but with relapsed dis-
ease. Six patients are well and in CR at a range of 19–298 days
52 Poster Session Ipost HSCT. CD41 recovery appears to occur at a pace comparable
to that of matched-sibling HSCT recipients. This 2 step procedure
promotes the establishment of donor-recipient tolerance by in vivo
CTX exposure, but avoids any effects of G-CSF on donor lympho-
cytes, allows delivery of a precise dose of T cells to all patients, and
eliminates CTX exposure of the hematopoietic precursors. Patients
who lack matched-sibling donors can be successfully transplanted
on this protocol with little significant GVHD. Infection and relapse
remain problems, but likely can be reduced through transplantation
of patients earlier in their disease course.
Patient Data










Grade Outcome19 AML - PIF Myeloablative 2.0 1.41 0.26 0 Died-Relapse
@ d 1 6755 CML & AML - PIF Myeloablative 2.0 3.62 5.0 I NED @ d 1 29826 ALL - CR2 Myeloablative 2.0 2.16 6.9 II NED @ d 1 22144 AML - CR2 Myeloablative 1.8 3.83 4.4 II NED @ d 1 18632 SAA Myeloablative 2.0 1.72 0.13 III Died-Infection
@ d 1 10159 AML - Resist
Relapse 1Myeloablative 2.0 4.11 0.39 0 Died-Relapse
@ d 1 9160 Biph Leuk -
Resist Relapse 1Myeloablative 2.0 2.74 0.82 I Died-Infection
@ d 1 4248 AML-PIF Myeloablative 2.0 4.57 0.29 I NED @ d 1 5358 AML-CR2 Myeloablative 2.0 3.04 0.27 0 NED @ d 1 4667 AML-PIF Non-myeloablative 2.0 4.33 4.5 II Alive @ d 1
166-Relapse73 AML-PIF Non-myeloablative 2.0 4.38 0.059 0 Died-Relapse
@ d 1 5536 AML-Relapse
post Match
Sib HSCT
Non-myeloablative 2.0 3.04 0.01 0 NED @ d 1 19136
OptiMatch – OPTIMIZED SELECTION OF ALLELE MATCHED UNRE-
LATED DONORS FROM A LARGE DATABASE
Bochtler,W., Eberhard, H.-P., Beth,M.,Mueller, C.R. ZKRDZentrales
Knochenmarkspender-Register Deutschland, Ulm, Germany.
The standard for unrelated donor selection is defined by allele
level matching for, at least, HLA-A, -B and -DRB1 with a strong
tendency to also include HLA-C and/or -DQB1. Even for patients
where such donors will likely exist, the search is hampered by the
high prevalence of donors where some of these loci are only typed
at intermediate or low resolution, by serology or not at all. A large
registry like ZKRD with over 3 million donors can have lists of hun-
dreds or even thousands of similar donor candidates for a substantial
fraction of the patients making an efficient search strategy difficult.
ZKRD’s new OptiMatch system addresses the issues raised by
a three layer concept:
(1) The DNA-based search engine uses serology-to-DNA map-
ping for the identification of donor candidates. The degree of
matching can be determined using combinatorial or biostatistical
methods. Moreover, the probability of allele level matching of
each candidate can not only be determined for each locus based
on the allele frequencies of the German population but also much
more reliably based on allele resolution haplotype frequencies for
HLA-A-B-DRB1, HLA-C-B and HLA-DRB1-DQB1.
(2) The web-based front end allows extensive configuration of the
way match lists are filtered and sorted, for example: Primary match-
ing can be based on the probability of matching 6/6, 8/8 (including
C or DQB1) or 10/10 (including both) alleles, and then the proba-
bility of 1 or, finally, 2 allele mismatches. Filters can be applied for
gender, CMV status and loci already typed.
(3) The sophisticated security architecture is based on strong au-
thentication of users and encrypted data transmission.The new OptiMatch search engine has been in use since late
2006. Its ability to identify some very likely matching donors among
myriads of multiple allele codes gives a stunning power to profes-
sional search coordinators. Even in most difficult cases it is apparent
upfront which degree of matching can possibly be sought for, which
donors should be considered first and which time frame and cost
volume should be expected.
During its ongoing test phase, the web-based front end is only
available in ZKRD’s intranet but will be released to outside beta tes-
ters before the end of 2007.137
POTENTIAL ROLE OF A MISMATCHED HLA-SPECIFIC CTL CLONE DEVEL-
OPED PRE-TRANSPLANT IN GRAFT REJECTION FOLLOWING CORD
BLOOD TRANSPLANTATION
Murata, M., Narimatsu, H., Terakura, S., Sugimoto, K., Naoe, T. Na-
goya University Graduate School of Medicine, Nagoya, Aichi, Japan.
Graft rejection is a significant complication in cord blood trans-
plantation (CBT), but little is known about the mechanism of rejec-
tion. In the present study, to investigate the potential role of T
lymphocytes in graft rejection, we isolated a CD81 cytotoxic T lym-
phocyte (CTL) clone from a patient with graft rejection after CBT
from an HLA-mismatched unrelated donor. Peripheral blood
mononuclear cells (PBMCs) obtained from the patient just after
the onset of graft rejection were cultured in interleukin-2 contain-
ing media without stimulator cells, and two CTL clones were iso-
lated by limiting dilution. One clone, designated N19D8, lysed
Epstein Barr virus transformed lymphoblastoid cells (B-LCL)
from the donor, but failed to lyse B-LCL from the patient, suggest-
ing that this CTL clone has the possibility of involvement in the im-
munological graft rejection. Fluorescent in situ hybridization for sex
chromosome indicated that N19D8 clone was originated from the
patient. In a cytotoxicity assay, N19D8 CTL lysed all of four B-
LCL lines from unrelated individuals that shared HLA-B*1501
but failed to lyse B-LCL from eight unrelated individuals without
B*1501. These data suggested that N19D8 CTL recognized
HLA-B*1501 molecule as an alloantigen, which was expressed in
donor cells but not in patient cells. The patient B-LCL transfected
with HLA-B*1501 cDNA alone were clearly lysed by N19D8 CTL,
and COS cells transfected with HLA-B*1501 cDNA alone stimu-
lated interferon-g production of N19D8 CTL. Thus, we concluded
that the N19D8 CTL clone recognizes mismatched HLA-B*1501
molecule as an alloantigen. We next determine whether the
N19D8 clone was developed prior to transplantation. The micro-
chimerism analyses specific for HLA-B*1501 gene and PCR assays
specific for the N19D8 CTL clone’s uniquely rearranged T cell re-
ceptor Vb17 chain gene on DNA from pre-transplant PBMCs re-
vealed that the patient was exposed to HLA-B*1501 prior to CBT
and N19D8 clone was developed in the patient’s blood before trans-
plantation. Interestingly, her daughter has HLA-B*1501 in an in-
herited paternal allele, suggesting that the patient might be
exposed to HLA-B*1501 during her pregnancy. In conclusion, the
present study demonstrated the potential role of pre-transplant
CTL in graft rejection following CBT. Further studies focusing
on mismatched HLA-specific CTLs should help establish the opti-
mal strategy to overcome graft rejection in CBT.138
CHARACTERISTICS OF 11 CASES OF PRE-ENGRAFTMENT LYMPHOCYTO-
SIS AFTER REDUCED-INTENSITY CORD BLOOD TRANSPLANTATION
Yamamoto, H., Wake, A., Ishiwata, K., Tuji, M., Takagi, S., Kato, D.,
Matsuhashi, Y., Sea, S., Matsuno, N., Uchida, N., Masuoka, K.,
Yoneyama, A., Taniguchi, S. Toranomon Hospital, Minato-ku Torano-
mon, Tokyo, Japan.
We have reported higher incidence of immune-mediated compli-
cations, such as pre-engraftment immune reaction (PIR), character-
ized by high-grade fever, skin eruption, diarrhea, jaundice and body
weight gain developing before engraftment or hemophagocytic
